204-IL) and Recombinant Human CD40 Ligand/TNFSF5 (Catalog #
6245-CL) were stained with Mouse Anti-Human TSPAN33 Monoclonal Antibody (Catalog # MAB8405) followed by Allophycocyanin-conjugated Anti-Mouse IgG Secondary Antibody (Catalog #
F0101B) and Mouse Anti-Human CD19 PE-conjugated Monoclonal Antibody (Catalog #
FAB4867P). Quadrant markers were set based on control antibody staining (Catalog #
MAB0041)." class="big_lightbox">

204-IL) and Recombinant Human CD40 Ligand/TNFSF5 (Catalog #
6245-CL) were stained with Mouse Anti-Human TSPAN33 Monoclonal Antibody (Catalog # MAB8405) followed by Allophycocyanin-conjugated Anti-Mouse IgG Secondary Antibody (Catalog #
F0101B) and Mouse Anti-Human CD19 PE-conjugated Monoclonal Antibody (Catalog #
FAB4867P). Quadrant markers were set based on control antibody staining (Catalog #
MAB0041)." alt="Human peripheral blood mononuclear cells (PBMCs) either (A) untreated or (B) treated overnight with Recombinant Human IL-4 (Catalog #
204-IL) and Recombinant Human CD40 Ligand/TNFSF5 (Catalog #
6245-CL) were stained with Mouse Anti-Human TSPAN33 Monoclonal Antibody (Catalog # MAB8405) followed by Allophycocyanin-conjugated Anti-Mouse IgG Secondary Antibody (Catalog #
F0101B) and Mouse Anti-Human CD19 PE-conjugated Monoclonal Antibody (Catalog #
FAB4867P). Quadrant markers were set based on control antibody staining (Catalog #
MAB0041)." class="big_thumb" />